期刊文献+

Th1/Th9/Th17细胞失衡对实验性自身免疫性重症肌无力幼鼠的影响及机制初探 被引量:2

Effects of Th1/Th9/Th17 cells imbalance on young rats with experimental autoimmune myasthenia gravis and its mechanism
下载PDF
导出
摘要 目的:对实验性自身免疫性重症肌无力(myasthenia gravis,MG)幼鼠采用双类似物(Lys262-Ala207)经鼻黏膜诱导免疫耐受后,了解实验幼鼠Th1/Th17/Th9细胞及产生相关细胞因子的细胞变化情况及其与EAMG幼鼠发病的相关性,探讨其调控作用机制。方法:将30只幼年雌性C57BL/6小鼠采用完全随机分组方法分为3组:模型组、耐受组和对照组。模型组经腹腔注射含1.0 mg/kg mAb35的Ringer’s液0.2 ml,建立EAMG模型;耐受组在致敏前10 d先经鼻黏膜滴入Lys262-Ala207诱导黏膜耐受,再按照模型组方式进行处理;对照组注射不含mAb35的Ringer’s缓冲液0.2 ml。采用流式细胞仪检测小鼠脾脏细胞中分别代表Th1/Th17/Th9细胞功能的CD4+干扰素(interferon,IFN)-γ+细胞、CD4+白介素(interleukin,IL)-17+细胞和CD4+IL-9+细胞的含量。采用双抗体夹心ELISA法检测脾细胞培养上清中IFN-γ、IL-17、IL-9的水平。结果:(1)MG的临床表现对照组明显轻于模型组和耐受组,而耐受组经双类似物免疫耐受后,其临床症状也较模型组明显减轻。(2)模型组、耐受组和对照组的CD4+IFN-γ+细胞含量3组间比较差异有统计学意义(P=0.00),即:模型组分别比耐受组和对照组高(P=0.00),而耐受组也比对照组高(P=0.00);(3)模型组、耐受组和对照组的CD4+IL-17+细胞含量3组间比较差异有统计学意义(P=0.00),即:模型组分别比耐受组和对照组高(P=0.00),而耐受组也比对照组高(P=0.00);(4)模型组、耐受组和对照组的CD4+IL-9+细胞含量3组间比较差异有统计学意义(P=0.00),即:模型组分别比耐受组和对照组高(P=0.00),而耐受组也比对照组高(P=0.00)。(5)模型组、耐受组和对照组的脾细胞上清中细胞因子IFN-γ、IL-17、IL-9的水平3组间比较差异有统计学意义(P=0.00),即:模型组分别比耐受组和对照组高(P=0.00),而耐受组也比对照组高(P=0.00)。结论:采用Lys262-Ala207对实验幼鼠进行鼻黏膜耐受后不仅能有效的缓解其MG的临床症状,同时还能下调导致实验幼鼠发病的CD4+IFN-γ+细胞、CD4+IL-17+细胞和CD4+IL-9+细胞含量水平以及细胞因子IFN-γ、IL-17、IL-9的水平,缓解Th1/Th17/Th9细胞功能失衡现象,从而达到预防和减轻实验幼鼠发病的作用。 Objective :To study the variation of Thl/Thl7/Th9 ceils which produce cytokines and to explore the correlation between these cells and pathogenesis of experimental autoimmune myasthenia gravis (EAMG) young mice after being treated with dual analogue(Lys262-Ala207) to create immune tolerance effect through nasal mucosa. Methods:Thirty young C57BL/6 female rats were randomized into three groups:model group,tolerance group and control group. Rats in model group were injected with 0.2 ml Ringer's containing mAb35( 1.0 mg/kg) to establish EAMG model;rats in tolerance group were given Lys262-Ala207 intranasally for ten successive days before immunization then were injected 0.2 ml Ringer's containing mAb35(1.0 mg/kg);rats in control group were intraperi-toneally injected 0.2 ml Ringer's without containing mAb35 (1.0 mg/kg). Cells of CD4+ IFN-γ+, CD4+ IL-17+ and CD4+ IL-9+, which respectively represent the cells of Thl/Th17/Th9 in spleen cell of young rats were detected by flow cytometry. IFN- γ,IL-17 and IL-9 in supernatant of spleen cell were detected by Antibody-sandwich ELISA. Results:(1)Clinical symptom of myas- thenia was less obvious in control group than in model group and tolerance group and clinical symptom of myasthenia was alleviated in tolerance group than in model group after being given dual analogue. (2)There were significant differences in the content of CD4+ IFN-γ+ among three groups (model group, tolerance group and control group)(P=0.00) ;content of CD4+ IFN-γ+ was higher in model group than in the other groups (P=0.00) and content of CD4~ IFN-γ+ was higher in tolerance group than in control group (P=0.00). (3) There were significant differences in the content of CD4+ IL-17+ among three groups (model group, tolerance group and control group) (P=-0.00) ;content of C D4+ IL-17+ was higher in model group than in the other groups (P=0.00) and content of C D4+ IL-17+ was higher in tolerance group than in control group(P=0.00). (4)There were significant differences in the content of CD4+ IL-9+ among three groups(model group, tolerance group and control group)(P=0.00) ;content of CD4+ IL-9+ was higher in model group than in the other groups(P=0.00) and content of CD4+ IL-9+ was higher in tolerance group than in control group(P=-0.00). (5)There were signifi- cant differences in the content of IFN-γ, IL-17 and IL-9 in supernatant of spleen cell among three groups(model group,toler- ance group and control group)(P=0.00) indicating that the content was higher in model group than in the other groups(P=0.00) and the content was higher in tolerance group than in control group(P=-0.00). Conclusions:Clinical symptom of myasthenia is relieved ef- fectively, content of CD4+ IFN-γ+, CD4+ IL-17+ and CD4+ IL-9+ as well as the content of IFN-γ,IL-17 and IL-9 which lead to sickness of rats is reduced and unbalance of cell of Thl/Yhl7/Th9 is relieved after young rats being treated with dual analogue(Lys262-Ala207) to create immune tolerance through nasal mucosa. This clarifies the role of dual analogue in the mechanism of immune tolerance of young rats.
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2014年第2期167-172,共6页 Journal of Chongqing Medical University
基金 重庆市卫生局科研基金重点资助项目(编号:2011-1-077)
关键词 实验性自身免疫性重症肌无力 鼻黏膜耐受 双类似物 Th1 TH17 TH9细胞 experimental autoimmune myasthenia gravis nasal tolerance dual analogue Th 1/Th 17/Th9 cells
  • 相关文献

参考文献23

  • 1De Baets M,Stassen M,Losen M,et al.Immunoregulation in experi- mental autoimmune myasthenia gravis -about T cells, antibodies,and endplates[J].Ann N Y Acad Sci, 2003 ( 998 ) : 308 -317.
  • 2Baggi F,Annoni A,Ubiali F,et al.Breakdown of tolerance to a self- peptide of acetylcholine receptor alpha-subunit induces experimental rnyasthenia gravis in rats[J].J Immunol, 2004,172 (4):2697-2703.
  • 3Milani M,Ostlie N,Wu H,et al.CD4+T and B ceils cooperate in the immunoregulation of experimental autoimmune myastheniagravis[J].J Neuroimmunol, 2006,179(1-2) : 152-162.
  • 4Milani M,Ostlie N.Wang W,et al.T cells and cytokines in the pathogenesis of acquired myasthenia gravis[J].Ann N Y Acad Sci, 2003 (998) :284-307.
  • 5Paas-Rozner M,Sela M, Mozes E.The nature of the active suppres- sion of responses association with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes [J].Proc Natl Acad Sci USA,2001,98(22) : 12642-12647.
  • 6黄志,徐秀娟.nAChR单克隆抗体建立重症肌无力被动转移小鼠模型的研究[J].第三军医大学学报,2006,28(13):1397-1400. 被引量:9
  • 7Lennon VA, Lambert EH, Leiby KR, et al.Recornlinant human acetylcholine receptor alphasubunit induces chronic experimental au- toimmune myasthenia gravis[J].J Immunol, 1991,146 ( 7 ) : 2245 -2248.
  • 8魏秀丽,黄志,李欣,刘玮.Foxp3基因及调节性T细胞在重症肌无力被动转移幼鼠发病中的作用机制[J].第三军医大学学报,2010,32(4):353-356. 被引量:6
  • 9Mu L,Sun B, Kong Q, et al.Disequilibrium of T helper type 1,2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis [J].Immunology, 2009,128 ( sl ) : e826 - e836.
  • 10Yang Y,Ochando JC,Bromberg JS,et al.Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFNgamma/Statl signals [J].Blood, 2007,110 ( 7 ) : 2494-2500.

二级参考文献48

  • 1王增钰,乔健.乙酰胆碱受体制剂对实验性自身免疫性重症肌无力的抑制作用[J].上海免疫学杂志,1994,14(3):129-133. 被引量:10
  • 2黄志,徐秀娟.nAChR单克隆抗体建立重症肌无力被动转移小鼠模型的研究[J].第三军医大学学报,2006,28(13):1397-1400. 被引量:9
  • 3Souroujon MC, Maiti PK, Feferman T, et al. Suppression of myasthenia gravis by anti-specific mucosal tolerance and modulation of cytokines and costimmulatory factors. Ann N Y Acad Sci, 2003, 998:533-536.
  • 4Duan RS, Link H, Xiao BG. Long-term effects of IFN-gamma, IL-10, and TGF-beta- modulated dendritic cells on immune response in Lewis mrs. J Clin Immunol, 2005, 25:50-56.
  • 5Liu R, La Cava A, Bai XF, et aL Cooperation of invariant NKT cells and CD4^ + CD25^ + T regulatory cells in the prevention of autoimmune myasthenia. J Immunol, 2005,175:7898-7904.
  • 6Yamagiwa S, Gray JD, Hashimoto S, et aL A role for TGF-β in the generation and expansion of CD4 ^+ CD25^ + regulatory T Cells from human peripheral blood. J Immunol, 2001,166:7282-7289.
  • 7Maiti PK, Feferman T, Im SH, et aL Immunosupression of rat myasthenia gravis by oral administration of syngeneic acetylcholine receptor fragment. Neuroimmunol, 2004, 152 : 112- 120.
  • 8Ben-David H, Aruna BV, Seger R, et al. A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses. Proc Natl Acad Sci USA, 2006,103 : 18232-18237.
  • 9Poulas K, Tsouloufis T, Tzartos .l. Treatment of passively transferred experimental autoimmune myasthenia gravis using papain. Clin Exp Immunol,2000 ,120 :363-368.
  • 10Kaminski HJ, Li Z, Richmonds C, et aL Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol, 2004, 189:333-342.

共引文献15

同被引文献28

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部